Podcasts about Chemotherapy

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Mitch Shulman can be heard every weekday morning at 7:50 on The Andrew Carter Morning Show.

Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the June open access episode of Chattering With iCatCare, Yaiza Gómez-Mejías is joined by Mariana Lopes and Joanna Morris to explore feline oncology and the practical roadmap for using oral chemotherapy agents in general practice.  The conversation focuses on providing realistic treatment options for patients where referral may not be accessible, highlighting how oral protocols can achieve efficacy and maintain quality of life within a primary care setting. They also discuss why cats must not be treated as small dogs regarding drug toxicity and the specific challenges of monitoring feline patients who often hide side effects.For further reading material please visit:Oral chemotherapy agents in cats: clinical uses, administration and side effectsHost:Yaiza Gómez-Mejías, LdaVet MANZCVS (Medicine of Cats), RCVS CertAP (Feline Medicine), iCatCare Veterinary Community Co-ordinatorSpeakers:Mariana Lopes, DVM, MSc, MVM, MRCVS, DipECVIM-CA (Onc), European Specialist in Small Animal Oncology, University of GlasgowJoanna Morris, BSc, BVSc, PhD, FRCVS, FHEA, DipECVIM-CA (Onc), Professor of Veterinary Oncology, University of Glasgow

Today on National Cancer Survivor's Day, we're joined by a remarkable performer whose strength, vulnerability, and resilience have inspired millions around the world. She has taken the stage as a backup vocalist for numerous top artists and most recently dazzled the crowds on the biggest tour in music history with global superstar Taylor Swift. However, audiences were moved even more deeply when she chose to publicly share something far more personal – her breast cancer journey. After Jeslyn Gorman's diagnosis become known through The Eras Tour docuseries, fans witnessed the emotional reality of navigating cancer while stepping away from a career and community she loves so deeply. From continuing to tour in the early days of diagnosis, to facing treatment side effects and returning to the stage immediately following treatment, her story is one of courage, grace and resilience. Today, Jeslyn opens up about the support she received, what survivorship looks like now and most importantly, shares an empowering message for young women about listening to their bodies, advocating for their health, and never underestimating the importance of early detection. Key Takeaways: Early detection can save lives. You can experience joy and fear at the same time. A strong support system makes a major difference. Recovery is gradual and requires patience. Cancer changes your life, but it doesn't define it. Chapters 00:00 – Jeslyn's Breast Cancer Diagnosis 05:24 – Continuing to Perform After Diagnosis 07:38 – Going Public With Her Cancer Story 13:22 – Breast Health and Self-Advocacy 18:07 – Support From Family, Friends, and the Tour Community 22:17 – Staying Positive During Treatment 25:17 – Chemotherapy and Physical Recovery 31:49 – Hair Loss and Identity Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship. 37:29 – Life After Treatment and Survivorship

Chemo doesn't have to mean hair loss. This week's guest, Kate Dilligan, Founder & CEO of Cooler Heads, describes what she wished had existed during her cancer treatment. Cooler Heads is the home of Amma, an FDA-cleared Scalp Cooling System that helps cancer patients reduce hair loss during chemotherapy. Hear what most people don't realize about hair loss during chemo, and the logistics of how Amma works. Kate also shares how her team measures the success of Amma and Cooler Heads. Tune in to this episode to help keep cancer treatment more private for those undergoing chemotherapy, and to help manage a very disruptive side effect of some treatment.   Learn more: Kate Dilligan Cooler Heads Cooler Heads LinkedIn   Today's Hot Flash and other stats from: Oxford Academic

Howie and Harlan are joined by Mark Siegel, director of Yale's internal medicine residency program, to discuss his approach to mentoring young physicians and building a medical community grounded in purpose and compassion. Harlan examines a breakthrough targeted therapy that could reshape the treatment of pancreatic cancer and other hard-to-treat cancers; Howie tracks the Ebola outbreak in the Democratic Republic of the Congo and argues that policy decisions are hampering the global response. Show notes: A Cancer Breakthrough Pancreatic cancer: Symptoms and causes "Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer" "Multi-Selective RAS(ON) Inhibitor Nearly Doubles Survival Time in People With Metastatic Pancreatic Cancer" "KRAS mutation: from undruggable to druggable in cancer" Mark Siegel Mark Siegel: Program Director Notes Mark Siegel on Substack Academic medicine Signaling system Mark Siegel: "What I've Learned in 63 Years" Yale School of Medicine: Residency & Fellowship Programs Mark Siegel: "A Sudden Loss Of Vision"  Health & Veritas Episode 224: Nicholas Christakis: The Science of Human Connection Ebola WHO: Bundibugyo virus disease outbreak, Democratic Republic of the Congo WHO: Ebola, The Democratic Republic of the Congo, 2026   WHO: Alert and Response "'We are catching up'—WHO chief on DR Congo's Ebola fight"  "Uganda Closes Border With Congo as Ebola Fears Rise" "Kenyan Court Deals New Blow to Plans for U.S. Ebola Unit" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Howie and Harlan are joined by Mark Siegel, director of Yale's internal medicine residency program, to discuss his approach to mentoring young physicians and building a medical community grounded in purpose and compassion. Harlan examines a breakthrough targeted therapy that could reshape the treatment of pancreatic cancer and other hard-to-treat cancers; Howie tracks the Ebola outbreak in the Democratic Republic of the Congo and argues that policy decisions are hampering the global response. Show notes: A Cancer Breakthrough Pancreatic cancer: Symptoms and causes "Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer" "Multi-Selective RAS(ON) Inhibitor Nearly Doubles Survival Time in People With Metastatic Pancreatic Cancer" "KRAS mutation: from undruggable to druggable in cancer" Mark Siegel Mark Siegel: Program Director Notes Mark Siegel on Substack Academic medicine Signaling system Mark Siegel: "What I've Learned in 63 Years" Yale School of Medicine: Residency & Fellowship Programs Mark Siegel: "A Sudden Loss Of Vision"  Health & Veritas Episode 224: Nicholas Christakis: The Science of Human Connection Ebola WHO: Bundibugyo virus disease outbreak, Democratic Republic of the Congo WHO: Ebola, The Democratic Republic of the Congo, 2026   WHO: Alert and Response "'We are catching up'—WHO chief on DR Congo's Ebola fight"  "Uganda Closes Border With Congo as Ebola Fears Rise" "Kenyan Court Deals New Blow to Plans for U.S. Ebola Unit" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

What happens after breast cancer treatment ends? For many survivors, finishing treatment is a major milestone, but it does not always mean life immediately goes back to “normal.”In this episode of Baptist HealthTalk, host Johanna Gomez, a breast cancer survivor,  speaks with breast cancer survivors Andrea de Armas and Nancy Antoine, both treated at Baptist Health Herbert Wertheim Cancer Institute, talk about diagnosis, treatment, survivorship and the emotional journey that continues long after active care ends.They discuss:• Being diagnosed with breast cancer at a young age • The importance of self advocacy and getting checked • The physical and emotional toll of chemotherapy • Fear of recurrence and scan anxiety • Fertility, hormone therapy and long term care • Body image, reconstruction and restorative tattooing • The importance of mental health and survivor community • How survivors can move from surviving to thrivingBreast cancer survivorship can bring new challenges, but it can also bring strength, purpose, community and hope.For more health and wellness information, visit BaptistHealth.net/News.Breast Cancer Survivor & Host:Johanna GomezAward-Winning Host & JournalistGuests:Andrea de ArmasBreast Cancer Survivor Nancy AntoineBreast Cancer SurvivorIf you found this episode helpful, you may also like:Young Women and Breast CancerDiagnosed with Breast Cancer: What's Next?Breast Cancer Survivorship: 10-Years Later

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send Us Your Prayer Requests --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Miniature human brains grown in a Saskatoon lab are upending the way researchers see neurology and immunology. Neuroscientist Dr. Tyler Wenzel is using brain organoids to challenge decades of rodent-based research, charting a new course for precision medicine.   As a high school biology teacher, Wenzel's students learned how hearts pump blood and lungs move air. But apart from neurological electrical activity, neither Wenzel nor the textbooks had many clear answers about the brain.   During his graduate studies, Wenzel realized the same experimental question tended to produce opposite results for mice and humans. The key difference, he found, lay in how each species' responded to toxins and injury,  leaving him skeptical of neurological therapies tested on rodents. Now an assistant professor of psychiatry at the University of Saskatchewan, Wenzel focuses on youth degenerative brain disease and the limits of traditional research models.   He grows human brain organoids — "mini brains" — from pluripotent stem cells derived from sources like blood or skin. Measuring two millimetres apiece, those organoids resemble tiny blobs of chewing gum. "We will turn [cells from a patient] into pluripotent stem cells, and we will make their mini brain, and because it has their genetic information, we get a brain that has their pathology," Wenzel said.  "If you do that same mutation, often in a mouse, the pathology won't appear. So it allows us to actually get a pathology we can actually study," he said.   When Wenzel was first hired at the University of Saskatchewan in 2024, the budget-conscious researcher built his lab on a shoestring, picking up secondhand centrifuges, balances, fridges and freezers from industrial start-ups. That move saved him time, and hundreds of thousands of dollars.  "All the money that we started off with, it is literally going to just the research team and directly to the research," Wenzel said, crediting NSERC and SHRF for their support. "I am so grateful."   Today, Wenzel studies childhood cerebral X-linked adrenoleukodystrophy (ALD), a rare degenerative brain disease that strikes children, and is fatal when left untreated. His organoids may provide proof of concept for new ways to target the brain and nervous system, without the need for radiation, chemotherapy, and lifelong immunosuppresant drugs currently required for hematopoietic stem cell transplants.  "Chemotherapy and irradiation makes holes throughout your whole body. So we can do it in just your brain, just your spinal cord, and then we can inject the immune cells specifically into those locations," Wenzel said. "That eliminates many of the things that make chemotherapy uncomfortable, many of the things that make any sort of stem cell transplant uncomfortable."   This spring, Canada's Stem Cell Network singled out Wenzel's work with a Rising Star Award, saying his work demonstrates "leadership, creativity and potential for major impact". If his method shows promise in treating ALD, Wenzel's approach could pave the way for more targeted, effective and far less invasive treatments for a range of degenerative brain diseases.

What if one of the most toxic products in your home isn't your cleaning spray, your cookware, or your water bottle… but the lip gloss sitting in your purse right now? In this eye-opening and deeply alarming conversation, Darin Olien sits down with clean beauty innovator, attorney, and consumer advocate Laura D'Alamo to expose what may be one of the biggest blind spots in modern health and beauty. After surviving triple-negative breast cancer and a near-fatal battle with COVID, Laura embarked on a two-year investigation into the cosmetic industry that uncovered a startling regulatory gap surrounding lip products, microplastics, toxic ingredients, and consumer safety. Together, they explore how lip products are regulated as external-use cosmetics despite being chronically ingested, why 80–90% of lip products may contain microplastics, how outdated regulations fail to reflect modern usage patterns, and why ingredients banned in food can still legally appear in products applied directly to the lips. They also discuss the launch of the Lip Service Alliance, the future of food-grade lip care, and how consumers can drive industry-wide change through awareness and purchasing decisions.     What You'll Learn Why lip products may represent a major overlooked toxic exposure pathway How cosmetics regulations differ from food and pharmaceutical regulations Why lip products are treated as external-use products despite being ingested The hidden role of microplastics in lip glosses, lipsticks, and lip balms Why flavored lip products may increase chronic ingestion How lip tissue differs biologically from normal skin The shocking absorption rates associated with oral mucosal tissue Why titanium dioxide is banned in European food but still used in lip products How outdated usage assumptions fail to reflect modern beauty habits Why the fastest-growing lip product market is girls ages 9–17 The mission behind the Lip Service Alliance How consumers can influence change through their purchasing decisions     Chapters 00:00:04 – Welcome to SuperLife 00:00:33 – Sponsor: Manna Vitality and frequency-enhanced wellness 00:01:59 – Introducing Laura D'Alamo and today's hidden toxic threat 00:02:35 – Triple-negative breast cancer and Laura's life-changing diagnosis 00:02:42 – Surviving COVID in the ICU and a profound existential awakening 00:03:00 – The cosmetic regulatory blind spot that changed everything 00:03:49 – Lip products containing thousands of microplastics per application 00:04:14 – Titanium dioxide, food bans, and regulatory contradictions 00:04:50 – The creation of the Lip Service Alliance 00:05:20 – Building the first food-grade lip care alternative 00:05:38 – Laura's legal background and journey through clean beauty 00:07:10 – Creating one of the first modern clean deodorant brands 00:08:23 – Innovation, consumer behavior, and predicting market shifts 00:09:29 – Consulting global beauty brands and seeing industry patterns 00:10:06 – Cancer diagnosis, purpose, and personal transformation 00:11:34 – Chemotherapy, ICU survival, and reevaluating life's mission 00:13:15 – The moment everything clicked into focus 00:13:59 – Returning to law and studying cosmetic regulations 00:14:25 – Why cosmetic regulations rarely keep pace with innovation 00:15:00 – Outdated assumptions still shaping modern beauty products 00:16:02 – Regulations built around usage patterns from decades ago 00:16:49 – Why this is a global issue—not just a U.S. problem 00:17:13 – Discovering the biggest blind spot in beauty history 00:18:15 – The late-night realization that launched two years of research 00:19:16 – Lip products classified as external-use cosmetics 00:21:02 – Why lip products are inevitably ingested 00:21:37 – Food-flavored lip products and TikTok taste-test culture 00:22:58 – Regulatory frameworks largely ignoring ingestion 00:23:53 – The EU's outdated lipstick usage assumptions 00:24:49 – The lead-in-lipstick controversy revisited 00:25:16 – Modern beauty consumers layering multiple lip products 00:26:16 – Heavy metals, PFAS, plastics, and cumulative exposure 00:27:12 – The $14 billion lip industry explained 00:27:34 – Why ages 9–17 are the fastest-growing demographic 00:29:00 – The shocking microplastic content of many lip products 00:29:44 – Why "clean beauty" often creates consumer confusion 00:30:15 – Hidden plastics even inside clean-positioned products 00:32:24 – Titanium dioxide and the food-versus-cosmetics paradox 00:33:20 – Genotoxicity concerns and cancer-related research 00:34:08 – Why regulators continue allowing it in lip products 00:35:04 – "You may love your lip products—but do they love you back?" 00:35:26 – The biological difference between lip tissue and skin 00:36:34 – Lip tissue as a highly absorbent biological portal 00:37:52 – Why standard skin testing may be misleading 00:38:17 – Testosterone, nicotine, and oral absorption comparisons 00:39:08 – Chronic exposure through ingestion and absorption 00:40:12 – Common sense versus regulatory assumptions 00:41:13 – Why parents react differently when children are involved 00:42:25 – The disconnect between protecting children and protecting ourselves 00:43:19 – Plastic detox research and fertility improvements 00:44:12 – Chronic inflammation and long-term health implications 00:45:07 – Quick wins consumers can implement immediately 00:45:47 – Why Laura spent two years building solutions before speaking publicly 00:46:30 – Launching the Lip Service Alliance 00:47:14 – Consumer awareness as the first step toward change 00:48:10 – Voting with your wallet and shifting industry behavior 00:48:52 – New scientific publications currently in peer review 00:49:50 – Creating new testing models for lip-specific safety 00:50:10 – Lip tissue absorbing up to hundreds of times faster than skin 00:51:00 – Why flavoring products encourages ingestion 00:52:14 – Petroleum-derived ingredients and bioaccumulation concerns 00:54:03 – Creating YAM: a 100% food-grade lip care company 00:55:29 – Building completely plastic-free packaging solutions 00:56:47 – Bioavailable ingredients and supporting natural lip biology 00:58:02 – The "dual pathway" problem: ingestion and absorption 00:59:00 – Hidden solvents and natural flavor loopholes 01:00:07 – Developing future food-grade lip products 01:01:04 – Why food-safe colorants are often illegal in cosmetics 01:02:28 – Regulatory barriers blocking safer innovation 01:03:37 – Simple policy changes that could transform the industry 01:04:23 – Darin reflects on Laura's relentless mission 01:05:32 – Why food-grade ingredients may work better biologically 01:06:21 – Regulatory modernization still missing lip-specific reforms 01:07:07 – The frustration of slow-moving bureaucracy 01:07:36 – Europe's timeline for microplastic warnings and bans 01:08:44 – Why consumers cannot afford to wait until 2035 01:09:29 – The aerosol-can analogy and how industries can change 01:09:49 – The role of consumer awareness and public pressure 01:10:38 – Why many brands don't even realize what's inside their formulas 01:11:18 – Inflammation, chronic exposure, and final warnings 01:11:57 – Closing thoughts and the future of lip safety advocacy     Thank You to Our Sponsors Shakeology: Get 15% off with code DARINO1BODI at Shakeology.com. Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order.     Join the SuperLife Community Get Darin's deeper wellness breakdowns — beyond social media restrictions: Weekly voice notes Ingredient deep dives Wellness challenges Energy + consciousness tools Community accountability Extended episodes Join for $7.49/month → https://patreon.com/darinolien     Find More from Laura DiGirolamo Website: https://yombeauty.com/  Instagram: @meetlauradigi Join: Lip Service Alliance     Find More from Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness      Key Takeaway "The biggest health threats are often the ones hiding in plain sight. Lip products are uniquely positioned at the intersection of ingestion, absorption, and chronic exposure, yet most regulatory systems still treat them as if they simply sit on the surface of the skin. Whether or not every concern raised in this conversation proves true over time, one thing is undeniable: consumers deserve better science, better transparency, and better products. And when enough people demand change, industries always find a way to evolve."

Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"There are a lot of specifics that nurses need to keep in mind as they are administering this herpes simplex modified virus to patients because accidental exposure is of concern both to the patient, to their family members, as well as to healthcare workers. I always recommend nurses wear personal protective equipment, such as a gown, safety glasses, gloves, and/or a face shield," Heidi Finnes, PharmD, RPh, BCOP, director of clinical ambulatory practice at Mayo Clinic and assistant professor of pharmacy at Mayo Clinic Alix School of Medicine in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about oncolytic viral therapy.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 29, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of oncolytic viruses to treat cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 273: Updates in Chemotherapy and Immunotherapy ONS Voice articles: Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy Oncolytic Virus Kills Tumor Cells While Supporting T Cells What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma Clinical Journal of Oncology Nursing articles: Intralesional Therapy: Consensus Statements for Best Practices in Administration From the Melanoma Nursing Initiative Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting Oncology Nursing Forum article: Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma ONS book: Guide to Cancer Immunotherapy (second edition) ONS clinical practice resource: Safe Handling of Oncolytic Viruses ONS Huddle Card: Immunotherapy Association of Community Cancer Centers (ACCC) Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) Network for Collaborative Oncology Development and Advancement (NCODA) Patient Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "[Oncolytic viruses] can have direct lysis to the tumor cells themselves, or they can cause immunogenic activation. They release tumor-associated antigens and then proinflammatory signals, so think of T cells, natural killer cells, those sorts of things, that can convert to immunologically cold tumors. Those are tumors that are immune silenced into hot tumors which are now immune activated. By doing that, they recruit those T cells and other cells to the area to attack both the primary tumors. But that's also thought to be how they work on distant or noninjected sites as well. This immunomodulatory capacity has led to the reclassification of oncolytic viruses as a form of cancer immunotherapy. So, think of it kind of similarly to how we think of immune checkpoint inhibitors in recruiting immune cells and leaving our immune system in the on position. This is also kind of a form of immunotherapy." TS 4:35 "One of the toxicities I know that is of significant concern to patients, family members, and healthcare workers is the incidence of herpes infections. Systemic herpetic infections are extremely rare and usually more common in patients who may be immunocompromised. In patients who also have other immune-related diseases—such as vitiligo, vasculitis, pneumonitis, sometimes worsening psoriasis—because you're mounting an immune response with these types of things, sometimes you can see a worsening of those types of immune symptoms. But for the most part, these types of side effects are very well tolerated in most patients." TS 9:07 "Talimogene is generally transmitted via bodily fluids or touch. It's not airborne. Herpes simplex virus isn't an airborne type of virus. Another thing to consider is where are you going to inject this? Are you going to do this in your infusion therapy unit? Are you going to do it in a dedicated room? Who's going to escort the patient to the room? How is the virus going to arrive at the room? How will you clean the room and all of the laboratory equipment or any of the exam tables that may be in there? I think having all of that discussed and assigned mitigates the consternation that can sometimes occur—the fear that occurs with administering a virus that is thought to be fairly communicable." TS 15:44 "Helping patients understand how this works [is important] because hearing that you're receiving a virus, particularly a herpes simplex virus, can be scary to a patient. I think understanding that it's modified or essentially we're taking the parts out of it so that we can directly inject a portion that recruits immune cells to that area, because the goal is for the oncolytic virus to attack cancer cells and then destroy them by triggering an immune response in the body." TS 20:51 "Sometimes patients are very concerned about urine in the toilet, bodily fluids, kissing loved ones, holding hands, hugging, you know, am I going to infect my loved one because I'm getting this type of an oncolytic virus therapy? I like to reassure patients that they can continue to hold hands and hug their loved ones as normal. Viral DNA is usually only present on the injection site. And as I mentioned previously, we want to cover that injection site with an occlusive dressing, at least with talimogene, for up to seven days. And particularly, if those injection sites are at all oozing or weeping, active virus is usually only on that injection site itself." TS 24:14

In December 1996, a 37 year old pharmaceutical executive sat in a Borders bookstore reading medical textbooks on the floor, trying to understand a disease she had never heard of. Multiple myeloma carried a three year prognosis. Her daughter was 18 months old. Her father had just died of cancer. Within weeks, she pushed her doctors to say the quiet part clearly. This would likely end her life before her child entered kindergarten.Kathy Giusti refused to accept passive survival. She built a plan while the system offered fragments. She interviewed oncologists and fertility specialists at the same time. She pursued IVF to have a second child while preparing for treatment. She stayed employed to keep insurance coverage. Every decision carried financial, medical, and emotional risk.That same urgency exposed a deeper failure. Cancer research moved slowly. Academic centers guarded data. Clinical trials lacked coordination. Patients entered a system that demanded compliance without providing clarity. Giusti responded by building the Multiple Myeloma Research Foundation, not as a support group, but as an operating engine to accelerate drug development, fund research, and force collaboration across institutions.This episode tracks the tension between individual agency and systemic failure. Giusti describes how patients navigate diagnosis, insurance barriers, and fragmented care in real time. She explains how data, genomics, and clinical trials reshape cancer treatment while still leaving patients responsible for decisions they are not trained to make. She addresses disparities in access, the limits of early detection, and the reality that progress in oncology often depends on speed, funding, and alignment of incentives.The conversation moves between lived experience and structural critique. It names the cost of delay, the burden placed on patients to act as their own advocate, and the tradeoffs required to push a system forward that still protects itself first.⸻RELATED LINKSKathy GiustiMultiple Myeloma Research FoundationFatal to FearlessAmerican Society of Hematology⸻FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 19, Shlomit woke up unable to speak. The right side of her body went numb. An emergency room sent her home and called it stress. That moment did not end in a diagnosis that changed policy or triggered reform. It sent her into a decade long pursuit of understanding how the brain fails language and how the healthcare system fails patients who cannot advocate for themselves.Shlomit trained as a speech language pathologist and spent years inside acute care hospitals and ICUs, performing endoscopies and treating patients with brain injury, stroke, and dysphagia. She watched medical teams rotate in and out, deliver dense updates, and leave families nodding without comprehension. She stayed behind and translated. Every day, patients told her she was the only one who explained what was happening. That gap is not an accident. Hospital systems optimize for throughput, not understanding. Patients move through beds based on cost, not readiness. Discharge planning becomes a financial decision wrapped in clinical language. A stay under 48 hours can shift the insurance burden dramatically, leaving patients exposed to higher out of pocket costs. Shlomit left the system and built Patient Path NYC, a private patient advocacy service. She now spends 15 to 20 hours a week per client reading charts, coordinating care teams, and translating medical decisions into plain language. Her work sits in the uncomfortable space between healthcare policy and lived experience. Families pay out of pocket to understand their own care. Hospitals benefit from the clarity she provides while maintaining the same structural incentives that created the confusion.This conversation tracks the human cost of fragmented care, the economics behind discharge decisions, and the quiet reality that patients who cannot communicate clearly often lose control of their own outcomes.RELATED LINKSShlomit LibertyShlomit Liberty on LinkedInPatient Path NYCBoard Certified Patient AdvocateFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us Fan MailHow advances in science can improve hair recovery in chemotherapy Dr Nik Georgopoulos is a highly experienced scientist, cell biologist & molecular biologist. He has a degree in biochemistry & genetics from Leeds University & a PHD.Dr Georgopoulis has studied viruses and how they cause cancer. He looks at what happens when things go wrong. As cancer can affect 1 in 2 people, he looks to try to understand how cancer happens.Nik describes cancer as like a wound that will not stop healing. We discuss the effect that chemotherapy treatment has on the rapidly proliferating cells of the body, including the hair follicles. Scalp cooling can prevent the chemotherapy drugs from entering the keratinocytes, and the hair matrix. Cold cap can help to eliminate the risk of permanent alopecia (PCIA) with certain treatments.Nik has been involved in the development of anti-oxidants that utilises nanotechnology, which can be applied to increase the effectiveness of scalp cooling and help to support the hair during treatment.Connect with Dr Nik:InstagramLinkedInPaxman scalp cooling Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy:FacebookInstagramTwitterClubhouse- @Hair.TherapyHair Therapy WebsiteDonate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert! Polytar Medicated Shampoo

In 2020, developmental biologist Dr. Crystal Rogers drove the country roads outside Davis, California crying between grant rejections, wondering whether she was about to lose her lab, her career, and the scientific future she had spent years building. She had already done what academia tells young scientists to do. She earned the credentials. She landed a faculty position at UC Davis. She built a lab. Then the real test began.On this episode of Standard Deviation, Dr. Oliver Bogler examines the unspoken rules that determine which scientists survive academic research and which quietly disappear from it. The conversation follows Crystal Rogers and cancer biologist Dr. Michelle Mendoza as they collide with the “Hidden Curriculum” of biomedical science: the unwritten rhetoric, institutional signaling, and grant writing strategies that often decide who receives funding, tenure, and long term stability.Michelle Mendoza entered a tenure track position at the Huntsman Cancer Institute while raising 3 children, navigating a divorce, and trying to secure major NIH funding during COVID. What looked like objective scientific review turned out to depend heavily on persuasion, presentation, and insider fluency. Established researchers could promise massive research agendas based on reputation alone. Junior investigators faced a completely different standard.Oliver traces how the Life Science Editors Foundation and its JEDI program intervened by pairing scientists with former editors from journals including Cell and Nature. The work had little to do with commas or grammar. Editors challenged logic, structure, and scientific framing before grant reviewers could destroy an application in public.Both researchers eventually secured career defining grants. One realized she would keep her job and not have to move her family. The other celebrated by ordering a personalized “DEV BIO” license plate and driving through Davis blasting nineties hip hop and Beyoncé.The episode exposes how biomedical research funding rewards institutional fluency as much as scientific talent, and how hidden systems inside academic medicine continue shaping who gets to stay in science long enough to make discoveries.RELATED LINKSDr. Crystal Rogers LinkedInDr. Crystal Rogers Faculty PageDr. Crystal Rogers LabDr. Michelle Mendoza LinkedInDr. Michelle Mendoza Faculty PageHuntsman Cancer Institute Mendoza LabLife Science Editors FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BUFFALO, NY – May 13, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Laryngeal leiomyosarcoma: A rare case report and literature review.” The study was led by first author Bolat Shalabaev and corresponding author Zhuldyz Kuanysh, both from the National Research Oncology Center, Astana, Kazakhstan. In this report, the authors describe a rare case of high-grade laryngeal leiomyosarcoma (LLMS) in a 64-year-old man who presented with progressive dyspnea and hoarseness caused by a large supraglottic mass. Laryngeal leiomyosarcoma is an exceptionally uncommon malignant tumor of smooth muscle origin, with fewer than 70 cases reported worldwide since it was first described in 1939. Because most laryngeal malignancies are epithelial tumors such as squamous cell carcinoma, diagnosis of LLMS can be particularly challenging and requires extensive histopathological and immunohistochemical evaluation. Imaging studies revealed a heterogeneous laryngeal tumor causing near-complete obstruction of the airway. Histopathological analysis demonstrated high-grade spindle-cell proliferation with marked pleomorphism and pathological mitoses. Immunohistochemical testing showed strong expression of smooth muscle actin (SMA) and vimentin, while markers including CD34, myogenin, cytokeratins 5/6 and 7, and p40 were negative, supporting the diagnosis of high-grade pleomorphic leiomyosarcoma. The patient underwent extended laryngectomy with left neck dissection and formation of a permanent tracheostomy. Comprehensive staging with CT, MRI, and ultrasound showed no evidence of regional or distant metastases. Due to the tumor's aggressive pathological features—including a Ki-67 proliferation index reaching 60%—the multidisciplinary tumor board recommended adjuvant chemotherapy with doxorubicin and ifosfamide following surgery. “Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients.” Postoperative pathology confirmed a high-grade pleomorphic leiomyosarcoma classified as pT3N0M0 according to the AJCC 8th edition staging system. Importantly, surgical margins were negative, and no metastatic involvement was identified in the five examined lymph nodes. At the most recent follow-up, 12 months after surgery and completion of chemotherapy, the patient remained alive and free of recurrence or metastasis. The authors also reviewed recently published LLMS cases reported between 2021 and 2024. Their analysis confirmed persistent male predominance, frequent involvement of the glottic and supraglottic regions, and highly variable clinical outcomes ranging from long-term disease-free survival to rapid metastatic progression. The report further highlights the central role of immunohistochemistry in differentiating leiomyosarcoma from other spindle-cell neoplasms of the head and neck. Importantly, the study emphasizes that complete surgical resection with histologically negative margins remains the most important factor associated with favorable outcomes. While the role of chemotherapy in laryngeal leiomyosarcoma remains controversial, the authors note that individualized multidisciplinary treatment approaches may be particularly valuable in patients with high-grade or high-risk disease features. Overall, this report contributes important clinical insight into one of the rarest malignancies of the larynx. As the first documented case of laryngeal leiomyosarcoma reported from Central Asia, the study expands the limited global literature on this disease and underscores the importance of coordinated multidisciplinary care, detailed pathological evaluation, and long-term surveillance in optimizing patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28862 Correspondence to - Zhuldyz Kuanysh - zhuldyzkuanysh@icloud.com Abstract video - https://www.youtube.com/watch?v=i3AoqIXo3Ys

Due to a family emergency, we are not able to record this week. If you would, please keep my mother in law in your prayers. Her name is Janet and her cancer has been in remission for over a year but it has returned in three different areas. We appreciate you!

In 2008, Katy Talento walked away from Capitol Hill and into a Catholic convent. Within a year, she walked out. Within another decade, she sat inside the White House shaping health policy. Somewhere in between, she got labeled “infertile” after a single cycle of testing and spent years believing it.That label stuck. The pain that came before it never got investigated. Doctors offered birth control and moved on. No one asked why her body was struggling. No one followed the thread.Talento built her career inside the very systems she now critiques. She worked on federal health policy, global disease programs, and later advised the Trump administration on healthcare reform. She helped advance price transparency rules in a system where hospitals can still list 457 different prices for the same service.Then she left.Now she builds employer health plans that bypass insurers, PBMs, and traditional networks. Her approach replaces insurance contracts with direct payment, nurse navigators, and cost sharing models that promise simplicity but raise hard questions about risk and protection.This conversation sits in that tension.Talento describes a healthcare system shaped by layered incentives, where insurers, hospitals, and intermediaries profit from complexity. She argues that employers hold the leverage to disrupt it. The host pushes on what happens when patients fall outside those structures, when contracts disappear, and when community based models fail.The episode moves through infertility, misdiagnosis, insurance design, and the mechanics of employer sponsored care. It tracks how policy decisions made in Washington ripple into exam rooms, billing departments, and family lives.It also confronts a harder truth.Even insiders who understand the system can still get caught in it.RELATED LINKSAllBetter HealthKaty TalentoThem Before UsAn Arm and a LegRelentless Health ValueFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us Fan MailSend us Fan MailIn this inspiring episode of Living the Dream with Curveball, we are joined by Jenn Greenhut Tollin, a remarkable survivor of stage four breast cancer who transformed her diagnosis into a powerful mission of love and positivity. After facing the harsh realities of her illness, Jenn created Zero Negativity, a brand that promotes positivity through unique accessories while supporting cancer research.Jenn shares her deeply personal journey, detailing the challenges she faced as a healthy yoga instructor suddenly confronted with a life-threatening diagnosis. She reflects on the emotional turmoil of infertility struggles and how it ultimately led her to embrace life in a new light. With a mindset shift that transformed her battle with cancer into a journey of gratitude, love, and trust, Jenn emphasizes the importance of viewing obstacles as opportunities for growth.Throughout the episode, Jenn discusses her innovative approach to healing, including the significance of self-love and the power of community support. She introduces her company, Zero Negativity, and its mission to empower cancer patients and caregivers alike. From chemo tote bags filled with comfort items to fundraising events, Jenn is dedicated to making a positive impact in the lives of others facing similar struggles.Join us for a heartfelt conversation filled with hope, resilience, and practical advice for anyone navigating the challenges of cancer or supporting a loved one through their journey.What You'll Learn in This Episode:- The transformative power of a positive mindset in the face of adversity- How Jenn turned her cancer diagnosis into a mission of love and support- The importance of community and self-love during difficult times- Insights into Jenn's company, Zero Negativity, and its initiatives- Tips for caregivers and patients on navigating the cancer journey togetherFor more information on Jenn Greenhut Tollin and her work, visit www.lovezeronegative.com and www.zeronegativefoundation.org.Support the show

In this powerful episode, Dr. Lynn Hellerstein speaks with Glenn Sturm, bestselling author, astrophotographer, and 18 years on chemo and counting. Guided by values like “Sturms never quit,” Glenn shares how he pursues passion, spreads positivity, and refuses to let cancer define his life. He highlights the impact of a multidisciplinary cancer care team where specialists collaborate and patients are part of the decision-making. This approach can significantly reduce mortality and improve quality of life compared to solo care. From managing cancer fatigue to using simple remedies like ginger for nausea, Glenn shares practical ways to navigate treatment. Originally given 2.5 years to live, he's now looking at 30—crediting team-based care and self-advocacy. Despite its benefits, multidisciplinary care faces barriers like insurance and provider resistance particularly in the United States. While it's typical to find palliative care team and tumor boards in hospitals, it is more challenging to find a true multidisciplinary cancer care team. Glenn's mission is to raise awareness and encourage patients to seek better, more collaborative care through his books Warrior Hate War, Cancer Set Me Free and his upcoming work More Than Hope. Dr. Lynn Hellerstein, Developmental Optometrist, co-owner of Hellerstein & Brenner Vision Center, P.C., award-winning author and international speaker, holds powerful and inspiring conversations with her guests in the areas of health, wellness, education, sports and psychology. They share their inspirational stories of healing and transformation through their vision expansion. Vision Beyond Sight Podcast will help you see with clarity, gain courage and confidence. Welcome to Vision Beyond Sight! Also available on Apple Podcasts, iTunes, Google Podcasts, Spotify, iHeart Radio, Audible and Stitcher.

In a wooded campground cabin in the early 2000s, 19 year old Ben Unger stood in the doorway and watched 20 naked men form a circle around a crying teenager. A counselor held up two tangerines and shouted, “These are your balls.” The exercise claimed to cure same sex attraction by forcing young men to “reclaim” their masculinity from overbearing mothers. Phones had been confiscated. Parents had paid thousands of dollars. Religion supplied the script. Pseudoscience supplied the props.Ben had grown up in an Orthodox Jewish community in Brooklyn and later studied in Israel to become a rabbi. When he admitted he felt attracted to men, rabbis told him to eat 7 figs a day, immerse in a ritual bath 5 times daily, or marry a woman and trust that “if there's friction, it works.” At 19, he entered conversion therapy through an organization called Jews Offering New Alternatives to Homosexuality, known as JONAH. He left with depression, religious trauma, and 6 months of silence toward the mother he had been taught to blame.Years later, represented by the Southern Poverty Law Center, Ben helped sue JONAH for consumer fraud in a landmark New Jersey case. The argument centered on evidence, not theology. Sexual orientation cannot be changed. The jury deliberated for 3 hours and ruled against the organization. The verdict helped reshape how states regulate conversion therapy and protect minors from psychological harm disguised as treatment.Today, Ben runs Buff Personal Training in New York City, a gym built on autonomy, mental health, and self respect. His story traces the arc from institutional control to self authorship. The conversation examines religion, LGBTQ rights, conversion therapy, consumer protection law, and the lasting cost of being told your identity is a disorder.RELATED LINKSBen Unger on LinkedInBen Unger on InstagramBUF Personal TrainingSouthern Poverty Law CenterJONAHFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nutrition during chemotherapy is one of the most misunderstood parts of cancer care. People are told to boost immunity, eat superfoods, and load up on supplements, but the wrong support at the wrong time can actually make treatment harder. In this episode, Dr. Carling and Alicia break down what nutrition should actually look like during chemo and why the goal is not to push the body harder, but to protect, stabilize, and preserve it. Dr. Carling explains that during chemotherapy, the body is under constant breakdown pressure. Gut lining, muscle tissue, nerve function, and brain health are all at risk. Nutrition's job is to protect those tissues, support digestion and absorption, stabilize blood sugar and energy, and reduce side effects like nausea, diarrhea, and fatigue. She also addresses chemo brain, the do's and don'ts of supplementation, why immune stimulation can be counterproductive, and how acupuncture works alongside nutrition to help the body actually absorb and use what it is being given. In this episode: Why immune balance, not immune stimulation, is the goal during chemotherapy, and what that looks like in practice The four main jobs of nutrition during chemo: tissue protection, digestion support, blood sugar stability, and side effect reduction Practical do's and don'ts including which proteins and fats to prioritize, why aggressive detox protocols are not appropriate, and how to manage nausea, diarrhea, and taste changes How acupuncture reduces nausea, supports digestion, calms the nervous system, and helps the body use nutrition more effectively   For full show notes, resources and links head to: https://vitalhealthcda.com/podcasts/   The Vital Health for You Podcast is for everyone. Get to know us more by connecting with us at our website or on our Facebook page. *Disclaimer: The statements made in this episode about specific products have not been evaluated by the U.S. Food & Drug Administration and are not intended to diagnose, treat, cure or prevent disease. All information provided is for informational purposes only and is not intended as a substitute for advice from your physician or other healthcare professional. 

Click here to receive today's free gift on the Radio Page:  Speaking God's Language – Throughout the Bible, God encourages us to bring before him our worship and praise, confession, thanksgivings, intercessions, and petitions. As Christians grow in the discipline of praying, it becomes clear that there is always more to learn. Joni Eareckson Tada shares insights and personal stories that will hone your skill of including scripture in your prayers. Use the coupon code: RADIOGIFT for free shipping! *Limit one copy per person* --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Podcast Host and Interviewee: Host: Franziska Ippen Interviewee: David Schiff   Podcast Description:  Dr. Franziska Ippen interviews Dr. David Schiff on his recent manuscript entitled "CATNON Conclusion: Closure on concurrent chemotherapy in IDHmt Grade 3 Astrocytoma"

Drew Flugstad-Clarke never planned to work in brain cancer. She planned to play Division I soccer at Georgetown. She planned to paint. She even tried investment banking, answering emails at 4am in a cubicle that never slept. Then in June 2022 her father, Jim, was diagnosed with glioblastoma at 57. He died 1 day shy of 7 months later, just before his 58th birthday. His symptoms began with emotion, not seizures. A steady HR executive suddenly cried. His golf game slipped. By the time he entered the hospital for a scan, he did not leave without surgery. A subway poster for a 5K became a lifeline. Drew showed up. She found a community. She later joined the American Brain Tumor Association as Community Manager for the Eastern Region. This conversation walks through anticipatory grief, caregiving in real time, strategic numbness, and what it costs to curate hope when the median survival clock is already ticking.RELATED LINKSDrew Clark Flukestad on LinkedInTopor StudiosAmerican Brain Tumor AssociationGeorgetown University Women's SoccerFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

- Cáncer de Mama en la Comunidad Hispana - Pruebas Diagnósticas: Grado y Receptores Hormonales - Opciones De Tratamiento Estándar, Incluyendo Cirugía, Reconstrucción, Quimioterapia, Radioterapia y Tratamientos Dirigidos - Cómo las Pruebas Diagnósticas y de Biomarcadores Orientan las Opciones de Tratamiento - Enfoques Actuales y Nuevos Para Su Tratamiento - El Importante Papel de los Ensayos Clínicos en la Comunidad Hispana - Cómo la Investigación Amplía las Opciones de Tratamiento - Consejos Para Manejar los Efectos Secundarios del Tratamiento, los Síntomas, las Molestias y el Dolor - Preocupaciones de las Mujeres y los Hombres Hispanos con Cáncer de Mama - Comunicación con Su Equipo de Atención Médica - El Papel Cada Vez Mayor de las Citas de Telemedicina/Telesalud - Guías para Prepararse para Citas de Telemedicina/Telesalud, Incluyendo la Tecnología, una Lista Preparada de Preguntas y la Discusión de OpenNotes - Preguntas Clave para Hacerle a su Equipo de Atención Médica Sobre Preocupaciones Relacionadas con la Calidad de Vida - Preguntas para Nuestro Panel de Expertos - Breast Cancer in the Hispanic Community - Diagnostic Testing: Grade & Hormone Receptors - Standard Treatment Options, Including Surgery, Reconstruction, Chemotherapy, Radiation & Targeted Treatments - How Diagnostic & Biomarker Testing Inform Treatment Options - Current & New Approaches to Your Treatment - The Important Role of Clinical Trials in the Hispanic Community - How Research Increases Treatment Options - Tips for Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Concerns of Hispanic Women & Men with Breast Cancer - Communicating with Your Healthcare Team - The Increasing Role of Telemedicine/Telehealth Appointments - Guidelines to Prepare for Telemedicine/Telehealth Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Healthcare Team about Quality-of-Life Concerns - Questions for Our Panel of Experts

"They are small, powerful little nuggets. They are actually small signaling proteins that our immune cells use to communicate. They really help regulate immune activation or inflammation and even the growth and survival of immune cells. When cytokines are used therapeutically in oncology, they help to stimulate immune cells such as T cells or natural killer cells to better recognize and attack cancer cells," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center of Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the cytokine drug class. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours (including 30 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 24, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge of cytokines to provide appropriate education and to safely administer related therapies. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis ONS Voice articles: FDA Approves Nogapendekin Alfa Inbakicept-Pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Oncology Drug Reference Sheet: Motixafortide ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) and 2024 Drug Supplement Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Clinical Journal of Oncology Nursing article: Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Nursing Considerations What's Old Is New Again, Unfortunately ONS Symptom Interventions Colony-Stimulating Factors Including Biosimilars for At-Risk Patients for Prevention of Infection: General Platelet Growth Factors for Prevention of Bleeding National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Cytokines are actually among some of the earliest forms of immunotherapy used in the treatment of cancer, and it really goes back to the 1980s and the 1990s. We're talking therapies like interferon [alpha] or interleukin-2 that were used to stimulate the immune system, with the idea that they would recognize and attack cancer cells, particularly in diseases like metastatic melanoma and renal cell carcinoma. What made these therapies unique was that although the overall response rates were relatively modest, when patients did respond, those responses could be very durable and sometimes long lasting. And that observation was really important for the field of oncology, because it was part of the process that demonstrated that the immune system could potentially control cancer in really meaningful ways." TS 1:49 "One nice new example of an engineered cytokine is nogapendekin alfa inbakicept, which is quite the tongue twister to say. … This agent is really interesting because it's an engineered interleukin-15 receptor agonist that works on stimulating natural killer cells and CD8-positive T cells. And what makes this so interesting is that it's used in combination with a medication that probably some of us are familiar with—good old BCG—for patients specifically with invasive bladder cancer. The other really interesting thing about this new therapy is the fact that it is one of our first ones to be engineered in a combination fashion. So the nogapendekin alfa is combined with a receptor component that is called inbakicept. And what happens is it forms a complex to enhance signaling and prolong the activity of the cytokine." TS 7:50 "When you're looking at our therapeutic cytokines, those tend to produce larger-scale systemic inflammatory effects leading to much more global side effect reactions, while your supportive care cytokines are more commonly associated with either bone marrow stimulation effects or hematologic changes." TS 14:01 "Regardless of what type of cytokine therapy may you be using, across the board, early recognition of the symptoms and proactive supportive care are really important. And this is where many of our oncology nurses play such a critical role in identifying changes that are happening in real time to the patient's condition and helping to coordinate, relay information to the rest of the providing team so that timely interventions can occur for the best care of the patient." TS 18:01 "The other fascinating thing about these cytokines is that they're not being used as monotherapy anymore. They're now being looked at in combination with other therapies or even other immunotherapies like our checkpoint inhibitors. They're being looked at in the sense that they may be able to help expand and further activate immune cells that our current therapies rely on. And so it's really interesting that while cytokines were some of the earliest forms of cancer immunotherapy, they're now being reimagined as part of modern combination strategies designed to really further help enhance the immune responses against cancer." TS 29:08

Welcome back to the Oncology Brothers podcast! In this second episode of our three-part series on colorectal cancer, we dived deep into the BRAF V600E mutation and its implications for metastatic colorectal cancer treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we discussed: The prevalence and outcomes associated with BRAF V600E mutations Recent advances in treatment options, including the BREAKWATER study The significance of biomarker testing and how it influences treatment decisions The new standard of care combining Encorafenib and Cetuximab with chemotherapy Management of overlapping side effects from targeted therapies Strategies for sequencing treatments in patients with MSI-high disease This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in colorectal cancer treatment. Don't miss out on the critical insights shared by our expert guest! Be sure to check out Part 1 of our series for an overview of the colorectal cancer treatment landscape, and stay tuned for Part 3, where we will focus on toxicity management and practical clinical pearls. Subscribe to our channel for more oncology insights and updates! This discussion was in support of an independent educational grant provided by Pfizer

What if cancer could be treated without destroying the rest of your body?In this episode, biotech founder Brad Niles (CEO of ARIZ Precision Medicine) breaks down a potential breakthrough in cancer treatment—one that targets cancer cells with precision instead of the “poison everything” approach of traditional chemotherapy.In early testing, his team saw:

Janine Durso spent 30 years inside pharmaceutical advertising shaping healthcare narratives before becoming a belief strategist and founder of The Believist. In November 2024, during a routine Zoom coaching session, she felt what she called a sharp, terrible pain in the right side of her head. Within hours she was in surgery for a ruptured brain aneurysm. She does not remember the ambulance, the ICU, or the first weeks that followed. She spent 5 weeks in intensive care, then 10 days relearning how to walk, calculate simple change, and manage basic cognition. Doctors later placed a stent and continue monitoring a second unruptured aneurysm.This episode traces the moment she told her husband something broke in my brain, the 14 days doctors called touch and go, and the slow mental rebuild that followed. It also examines insurance barriers that require 2 direct relatives with aneurysms before screening coverage, and why she now lobbies in Washington for change.RELATED LINKSJanine DursoThe BelievistBrain Aneurysm FoundationWhite Plains HospitalDr. Jared CooperFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Rory McGowan talks to Christian Tucat, the CEO of Home Healthcare Provider Sciensus, about a new report they've presented to parliament regarding the types of healthcare possible from home, and how that helps the NHS' 10 year plan to bring more care into the community.

Rebecca Benghiat holds a JD, passed the bar, and skipped corporate law to build mental health systems instead. She now serves as Chief of Staff and Head of Impact at Inner Foundation, where she helps direct capital toward emerging adults ages 18 to 30 and asks a hard question every day: Is this actually working?In this conversation, she dismantles the myth of easy fixes. She explains why mental health measurement resists clean metrics, why a PHQ 9 score starts a conversation but never finishes one, and why “scale” often flatters institutions more than it helps people. She breaks down how impact investing shapes care delivery, why schools need networked systems not slogans, and why friction might be developmentally necessary.The stakes are real. Vulnerable families navigate snake oil, glossy apps, and pay to play algorithms while carrying the burden of choice in crisis. Benghiat lives inside that complexity and refuses to simplify it.RELATED LINKSRebecca BenghiatInner FoundationAspen Ideas HealthThe Jed FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical Oncologist, exploring the nuances of chemotherapy in this context. We discuss key trials, shifting definitions of disease volume, and the implications for treatment decisions.

New research reveals that five G radiation at twenty-eight gigahertz -- the same frequency used in urban five G networks -- significantly worsens heart damage from chemotherapy drugs. In this episode, I break down a groundbreaking study showing how millimeter wave radiation amplifies the cardiotoxic effects of doxorubicin, a widely used cancer treatment. The researchers found that even short-term exposure to five G frequencies reduced protective enzymes and increased cell death signals in heart tissue. What makes this particularly concerning is that millions of cancer patients may be receiving these treatments while living in five G-dense environments. In This Episode How five G radiation at twenty-eight gigahertz amplifies chemotherapy heart damage The specific biological pathways affected by this dangerous combination Why this matters for cancer patients living near five G infrastructure Simple steps to reduce exposure during medical treatment Featured Study Read the full study: Rahimi A, Rafati A, Mortazavi SMJ, Edalat F, Jooyan N, Naseh M, Keshavarz S, Jahromi HM, Nabizadeh A, Dastghaib S, Karbalaei N See all studies at shieldyourbody.com/research

In this episode, host Janet Michael talks with Traci Toth, Executive Director of Wheels for Wellness, and Ann Lamanna, board chair and volunteer driver, about the vital free medical transportation service they provide to residents across the Winchester, VA region — and their upcoming 10th annual fundraiser, Tablescapes. About Wheels for Wellness Wheels for Wellness provides free transportation to medical appointments for people who lack other means of getting there. Their service area covers: Winchester Frederick County Clarke County Warren County Northern Shenandoah County Who they serve: Any ambulatory adult (ages 20–90+) who is not a Medicaid recipient and needs a ride to a medical appointment. They serve all income levels and age groups. Types of appointments covered: Dialysis (approximately 68% of current transports) Chemotherapy & radiation Doctor's appointments Dental & hearing appointments Diagnostic procedures (colonoscopies, imaging, etc.) How Volunteering Works Volunteers use their own vehicle and gas Completely flexible scheduling — no minimum hours required Volunteers sign up only for trips that fit their schedule Wheels for Wellness provides secondary accident liability insurance for all drivers Last year, volunteer drivers logged 130,000 miles Tablescapes 2026 — A Decade of Design 10th Annual Fundraiser

On this week's episode, Dr. Cox struggles to support his best friend through Chemotherapy. In the real world, Zach and Donald are joined by Brendan Fraser! Brendan reveals his love of photography, the time he worked with Mos Def, and what it's like to be stopped by Scrubs fans nearly 20 years after his first appearance on the show. See omnystudio.com/listener for privacy information.

At age 12, Dr. Chrystal Starbird stood by a pond after turning her mother in to the police. She watched tadpoles and fish move beneath the surface and found a strange kind of order. Science became her refuge long before it became her career. Years later, she built that refuge into a profession. She now serves as an Assistant Professor at the University of North Carolina, studies structural biology tied to cancer and Alzheimer's disease, and won Cell's first Rising Black Scientist Award in 2020. On paper, she fits the model of success. In practice, she had to fight for basic access at every stage.Conference travel required upfront cash she did not have. Networking favored pedigree over merit. Mentorship often depended on who knew your name in the room. Chrystal learned those rules, then chose to break them open for others.Oliver Bogler examines what Chrystal calls the advocacy tax. She has delivered over 70 invited talks. Nearly 40 percent focus on equity, mentorship, and policy. Academic reward systems do not count that labor toward tenure. She still does it.Through her leadership at the Life Science Editors Foundation, Chrystal helped build the JEDI program, which pairs underrepresented scientists with editors from journals like Cell and Nature. The program has supported over 100 awardees with more than 1,000 hours of mentorship. This episode exposes how biomedical science rewards output while ignoring the work required to make the system accessible. It also shows what happens when the people most affected refuse to step back.RELATED LINKSDr. Chrystal StarbirdStarbird LabLife Science Editors FoundationJEDI ProgramFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode features the 2025 ASHP Best Practice Award winning team at the Fred Hutchinson Cancer Center who is recognized for a program focusing on pharmacist prescriptive authority and optimizing care through identifying and prescribing oral chemotherapy for patients.   The initiative exemplifies ASHP's new strategic plan and its patient care pillar, advancing innovative pharmacy practices that expand access, improve outcomes, and elevate the role of pharmacists as integral members of the healthcare team.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

At 19, Jansher Naim went from sharp stomach pain to a Stage 4 fibrolamellar diagnosis that few doctors see and even fewer young adults survive. He pushed through 41 rounds of chemotherapy, a Whipple surgery, and months of isolation while his friends kept moving through normal college life. In the studio, Jansher sits beside his mother Sadia Siddiqui, who refused early defeat and helped overhaul his care team when the first plan offered little optimism. Now a Computer Science student at Columbia, Jansher lives in the uneasy space between remission and risk, managing fertility decisions, travel for ongoing care, and the strange pressure to look fine at 22. Together they describe what it takes to grow up fast inside a system that rarely knows what to do with young adults who refuse to disappear.RELATED LINKSJansher NaimSadia SiddiquiFibroFighters FoundationColumbia UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Stop applying to medical sales jobs online. You're doing it wrong.In this episode of Medical Sales U, I sit down with Todd Ford, National Sales Director at Guardant Health, to pull back the curtain on what it actually takes to lead and land a role in the high-stakes world of precision medicine and oncology diagnostics.Todd has hired over 150+ people at Guardant alone, and his data is clear: only 1 in 65 successful hires comes from an online application. So, how do you get in? We break down the "networking secret," the evolution of genomic testing (NGS), and the daily habits of the top 10% of sales reps who win President's Club year after year.In this episode, you'll learn:Why B2B sales (like copiers) is the ultimate stepping stone to Medical Sales.The "hidden" criteria Todd uses to hire D1 athletes and top-tier talent.How Precision Medicine shifted from Chemotherapy to Targeted Therapy.The reality of "The Hustle": Managing 160 flights a year while raising a family.Why your resume is the least important part of your job search.TIMESTAMPS:0:00 - Introduction: Meet Todd Ford of Guardant Health2:15 - The 10-Year Evolution: From Chemo to Precision Medicine4:40 - Career Roots: Why a Mentor told Todd to sell Copiers first7:00 - Scaling the MRD (Minimal Residual Disease) Team9:30 - How to Move from Sales Rep to National Director12:15 - The "Ante" to get to the table: Consistent Performance15:00 - Hiring Secrets: The "1 in 65" Networking Rule18:30 - Managing the Autonomy: Habits of a Remote Sales Leader21:00 - The Travel Reality: 160 Flights vs. Family Life24:00 - The President's Club: Ritz-Carlton Yachts & Rewards28:00 - Final Advice: Why Initiative is your best Interview ToolCONNECT WITH THE GUEST:Todd Ford on LinkedIn: https://www.linkedin.com/in/todd-ford-914b34/Guardant Health: https://guardanthealth.com/ABOUT MEDICAL SALES U:We help aspiring and veteran sales professionals break into and level up within the medical device, pharmaceutical, and diagnostic industries. Subscribe for weekly interviews with the leaders shaping the future of medicine. We help professionals transition into top-tier medical sales roles: medicalsalesu.com/#MedicalSales #PrecisionMedicine #Oncology #GuardantHealth #SalesLeadership #MedicalDeviceSales #JobSearchTips #PresidentClub #SalesHabits

A groundbreaking study reveals that twenty-eight gigahertz five G radiation can worsen heart damage from chemotherapy drugs, creating a dangerous interaction that affects millions. R Blank examines new research showing how five G's millimeter waves amplified the cardiotoxic effects of doxorubicin chemotherapy in laboratory studies. The findings reveal reduced antioxidant defenses, increased cell death signals, and disrupted heart rhythms when the two exposures combine. In This Episode How twenty-eight gigahertz five G radiation interacts with chemotherapy drugs The biological mechanisms behind amplified heart damage Why vitamin C showed protective effects in the study Featured Study Read the full study: Rahimi A, Rafati A, Mortazavi SMJ, Edalat F, Jooyan N, Naseh M, Keshavarz S, Jahromi HM, Nabizadeh A, Dastghaib S, Karbalaei N See all studies at shieldyourbody.com/research

Jessica Federer built her career inside the rooms where science, money, and power collide. As the first female Chief Digital Officer at Bayer, she helped steer a 120,000 person global company through the rise of digital medicine while confronting a harder truth: women were excluded from U.S. clinical trials until 1993. In this conversation, she explains how decades of “first in man” research shaped drug development, why women experience side effects at nearly 2x the rate of men, and how guidance on sex based differences did not arrive from the FDA until December 2025. She shares what it means to sit on a Yale Institutional Review Board, why clinical trial stipends over $3,000 get taxed, and why she believes participants deserve tax credits instead. From GLP 1 profits to $40,000,000 women's health funds that barely move the needle, this episode names the gaps and the opportunity hiding inside them. RELATED LINKSJessica Federer on LinkedInJessica Federer on InstagramYale School of Public HealthHealth of Women Investor SummitFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's episode, I'm sitting down with Cathy Williamson of The Middle Page blog for a conversation that is both powerful and deeply encouraging. As a triple negative breast cancer survivor, Cathy shares her journey from diagnosis through treatment, including chemotherapy and a double mastectomy. We also talk about the emotional side of it all—losing her hair, the realities of treatment, and the practical tips that helped her get through it. Her story is full of wisdom, perspective, and so much hope—and I know it will encourage you.  

Monique Gore Massey spent 2.5 years cycling through New York City emergency rooms while her body shut down. Fevers hit 105. Her weight dropped from 122 pounds to 72 in 3 months. Hair fell out in clumps. No one ran an ANA test. Doctors blamed stress, old sports injuries, migraines. When a physician finally named it lupus, she added that she hoped it was not. Months later, Monique heard the words “get your affairs in order.”In this episode, Monique details living with lupus nephritis, pericarditis, fibromyalgia, and the daily math of survival. She recounts arriving at a patient conference shortly after coming off crutches and requesting elevator access for support, only to face resistance at a health summit that claimed to center patients. She breaks down what it costs when industry extracts lived experience for free and calls it engagement. Listeners will hear what invisible illness looks like in real time, how bias delays diagnosis, and why advocacy without strategy leaves patients exploited instead of respected.RELATED LINKSMonique Gore MasseyLupus Foundation of AmericaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.